ECSP11011165A - Compuesto heterocíclico y uso del mismo - Google Patents
Compuesto heterocíclico y uso del mismoInfo
- Publication number
- ECSP11011165A ECSP11011165A EC2011011165A ECSP11011165A ECSP11011165A EC SP11011165 A ECSP11011165 A EC SP11011165A EC 2011011165 A EC2011011165 A EC 2011011165A EC SP11011165 A ECSP11011165 A EC SP11011165A EC SP11011165 A ECSP11011165 A EC SP11011165A
- Authority
- EC
- Ecuador
- Prior art keywords
- same
- heterocyclic compound
- raf
- symbol
- salt
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008307581 | 2008-12-02 | ||
| JP2009125256 | 2009-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011165A true ECSP11011165A (es) | 2011-07-29 |
Family
ID=42026212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011165A ECSP11011165A (es) | 2008-12-02 | 2011-06-29 | Compuesto heterocíclico y uso del mismo |
Country Status (40)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200904816A (en) * | 2007-06-05 | 2009-02-01 | Takeda Pharmaceutical | Fused heterocycle derivatives and use thereof |
| EP2181987B9 (en) * | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
| JP2015511632A (ja) * | 2012-03-30 | 2015-04-20 | 武田薬品工業株式会社 | メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 |
| CN113679717A (zh) | 2012-08-22 | 2021-11-23 | 康奈尔大学 | 用于抑制肌成束蛋白的方法 |
| EP3013798B1 (en) | 2013-06-28 | 2018-06-27 | BeiGene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| JP6380862B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物 |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
| CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| US9573946B2 (en) | 2014-02-20 | 2017-02-21 | Novita Pharmaceuticals, Inc. | Compounds and methods for inhibiting fascin |
| CA2954764A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| WO2016106359A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
| WO2020097398A1 (en) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
| WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN115724837B (zh) * | 2022-10-26 | 2024-07-23 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
| US4096264A (en) * | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| NZ503432A (en) | 1997-09-26 | 2002-11-26 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| RS51497B (sr) * | 1999-01-13 | 2011-04-30 | Bayer Healthcare Llc | w-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6797823B1 (en) * | 1999-01-22 | 2004-09-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives |
| JP4609691B2 (ja) * | 1999-07-01 | 2011-01-12 | 味の素株式会社 | 複素環化合物及びその医薬用途 |
| DE60039206D1 (de) | 1999-11-05 | 2008-07-24 | Astrazeneca Ab | Neue Quinazolin-Derivate |
| JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| MXPA02008021A (es) | 2000-02-15 | 2004-04-05 | Sugen Inc | Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas. |
| AU2001235838A1 (en) | 2000-03-06 | 2001-09-17 | Smithkline Beecham Plc | Imidazol derivatives as raf kinase inhibitors |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| AU2001281817B2 (en) | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| KR20030030027A (ko) | 2000-09-21 | 2003-04-16 | 스미스클라인비이참피이엘시이 | Ｒａｆ 키나제 저해제인 이미다졸 유도체 |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| EP1432703A1 (en) | 2001-09-05 | 2004-06-30 | Smithkline Beecham Plc | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| ES2309207T3 (es) | 2001-09-05 | 2008-12-16 | Smithkline Beecham Plc | Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf. |
| EP1487824B1 (en) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| DK1499311T3 (da) | 2002-03-29 | 2010-03-08 | Novartis Vaccines & Diagnostic | Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US7378233B2 (en) * | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
| DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
| DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| US7423150B2 (en) | 2003-10-16 | 2008-09-09 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
| US7846959B2 (en) | 2004-05-07 | 2010-12-07 | Exelixis, Inc. | Raf modulators and methods of use |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006071035A1 (en) | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
| WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
| CN101106990B (zh) * | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| KR100965040B1 (ko) | 2005-07-11 | 2010-06-21 | 미쓰비시 타나베 파마 코퍼레이션 | 옥심 유도체 및 그의 제조 방법 |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| WO2007058482A1 (en) | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
| ES2654847T3 (es) | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| TW200817409A (en) | 2006-08-04 | 2008-04-16 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| US20100203043A1 (en) | 2007-04-13 | 2010-08-12 | Ree Anne H | Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr) |
| US20110091377A1 (en) | 2007-05-11 | 2011-04-21 | The Johns Hopkins University | Biomarkers for melanoma |
| CA2686787A1 (en) | 2007-05-23 | 2008-12-04 | Novartis Ag | Raf inhibitors for the treatment of thyroid cancer |
| TW200904816A (en) | 2007-06-05 | 2009-02-01 | Takeda Pharmaceutical | Fused heterocycle derivatives and use thereof |
| JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| EP2184285B1 (en) | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
| CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
| US20110081362A1 (en) | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko not_active Expired - Fee Related
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en not_active Ceased
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/en unknown
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en not_active Expired - Fee Related
-
2015
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011165A (es) | Compuesto heterocíclico y uso del mismo | |
| DOP2009000227A (es) | Derivados de aril isoxazolina insecticidas | |
| CO6361854A2 (es) | Tiazoles sustituidos con heterociclilo como agentes fitosanitarios | |
| DE602008000754D1 (de) | Tropanverbindungen | |
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CO6480909A2 (es) | Derivados de tiazolilpiperidina como fungicidas. | |
| CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
| BRPI0907435A8 (pt) | derivados de 5-flúor pirimidina | |
| EA200801630A1 (ru) | Соединения пиперазина с гербицидным действием | |
| CR20110635A (es) | Quinazolinas sustituidas como fungicidas | |
| AR083234A1 (es) | Composicion pesticida y su uso | |
| WO2009028655A1 (ja) | 複素環化合物およびその用途 | |
| WO2009025358A1 (ja) | 複素環化合物およびその用途 | |
| BRPI0911679A2 (pt) | composto aciltiouréia, ou sal do mesmo, e seu uso | |
| BRPI0808172A2 (pt) | Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso. | |
| ECSP10010347A (es) | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina | |
| CU20100111A7 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares | |
| BR112013032758A2 (pt) | derivados de n-oxi-pirazolo-triazepino-diona | |
| ECSP10010626A (es) | Derivados de iminopiridina y su uso | |
| EA200900780A1 (ru) | Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства | |
| MX2013002511A (es) | Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado. | |
| UY30235A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| DOP2007000060A (es) | Inhibidores de la adenilato ciclasa soluble | |
| UY30236A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| UY32826A (es) | Compuestos heterocíclicos |